Prescription medication · Nonsteroidal Anti-Inflammatory Drug (NSAID)
meloxicam
Also sold as Mobic. Meloxicam treats the symptoms of osteoarthritis and rheumatoid arthritis.
Data updated 2026-05-15
- 55,835
- FDA reportsOften reported
- 17
- InteractionsSeveral interactions
- $10.63
- Generic price (NADAC)
What the data shows
meloxicam (Mobic) is a prescription Nonsteroidal Anti-Inflammatory Drug (NSAID), more reported than most tracked drugs (55,835 FDA reports), with 17 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
meloxicam (Mobic) is a prescription Nonsteroidal Anti-Inflammatory Drug (NSAID). Meloxicam treats the symptoms of osteoarthritis and rheumatoid arthritis.
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID). It helps to reduce pain and swelling.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$10.63/unit
Generic Available
Yes (11 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Meloxicam treats the symptoms of osteoarthritis and rheumatoid arthritis.
Common side effects
Diarrhea, Upper respiratory infection, Upset stomach
Key warnings
Meloxicam may increase your risk of serious heart problems, including heart attack and stroke, which can be fatal.
The sections below are summarized in plain English from meloxicam's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Meloxicam works by reducing substances in the body that cause pain and inflammation. It blocks the production of prostaglandins. Prostaglandins contribute to inflammation and pain.
Side Effects (from patient reports)
Based on 55,835 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for meloxicam, by number of reports
- Pain
Pain
4,670 reports
- Fatigue
Fatigue
4,578 reports
- Arthralgia
Arthralgia
4,222 reports
- Nausea
Nausea
3,807 reports
- Headache
Headache
3,323 reports
- Diarrhoea
Diarrhoea
3,226 reports
- Dyspnoea
Dyspnoea
2,663 reports
- Dizziness
Dizziness
2,641 reports
- Pain In Extremity
Pain In Extremity
2,575 reports
- Malaise
Malaise
2,486 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for meloxicam each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where meloxicam sits
meloxicam has more FDA adverse-event reports than 75% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is meloxicam; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 55,835 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
55,835
Reports Mentioning Death
3,542
6.3% of reports — not proof of cause
Hospitalization Reports
13,382
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | PAIN | 4,670 |
| 3 | FATIGUE | 4,578 |
| 4 | ARTHRALGIA | 4,222 |
| 5 | NAUSEA | 3,807 |
| 6 | HEADACHE | 3,323 |
| 7 | DIARRHOEA | 3,226 |
| 8 | DYSPNOEA | 2,663 |
| 9 | DIZZINESS | 2,641 |
| 10 | PAIN IN EXTREMITY | 2,575 |
| 12 | MALAISE | 2,486 |
| 13 | CHRONIC KIDNEY DISEASE | 2,336 |
| 14 | RHEUMATOID ARTHRITIS | 2,235 |
| 15 | VOMITING | 2,234 |
| 16 | RASH | 2,202 |
| 17 | CONDITION AGGRAVATED | 2,069 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Meloxicam may increase your risk of serious heart problems, including heart attack and stroke, which can be fatal. This risk may occur early in treatment and may increase with longer use. You should not take meloxicam if you are having heart bypass surgery. Meloxicam can also increase your risk of serious stomach and intestinal problems, including bleeding, ulcers, and holes, which can be fatal. These problems can occur without warning. The elderly and those with a history of ulcers are at greater risk.
Known Drug Interactions
Methotrexate Clinical Impact: Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction). Intervention: During concomitant use of meloxicam and methotrexate, monitor patients for methotrexate toxicity.
Mechanism: Meloxicam can cause methotrexate to build up in your body to unsafe levels. This can lead to serious issues like low blood cell counts and kidney damage.
NSAIDs and Salicylates Clinical Impact: Concomitant use of meloxicam with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see Warnings and Precautions ( 5.2 )].
Mechanism: Using these two drugs together increases the chance of serious stomach problems like bleeding or ulcers. Combining them does not provide any extra benefit for your pain or swelling.
Diuretics Clinical Impact: Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. However, studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. Furosemide single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam.
Mechanism: This pain reliever can sometimes block the effects of water pills, making it harder for your body to get rid of extra salt.
Intervention: Monitor patients with concomitant use of meloxicam with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions ( 5.12 )]. Aspirin Clinical Impact: Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated...
Mechanism: Combining these medicines increases the risk of stomach bleeding and does not provide any extra pain relief.
ACE Inhibitors, Angiotensin Receptor Blockers, or Beta-Blockers Clinical Impact: NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).
Mechanism: Meloxicam can reduce the blood-pressure-lowering effects of propranolol. This makes your blood pressure medicine less effective.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I take meloxicam with aspirin?
Can meloxicam affect my blood pressure?
Can I drink alcohol while taking meloxicam?
What should I do if I experience heartburn while taking meloxicam?
How long does it take for meloxicam to start working?
Can meloxicam cause weight gain?
Is meloxicam a narcotic?
Can I take meloxicam if I have kidney problems?
Can meloxicam cause drowsiness?
Will meloxicam cure my arthritis?
What are the common side effects of meloxicam?
Does meloxicam interact with other medications?
What drug class is meloxicam?
What pregnancy or breastfeeding source fields are listed for meloxicam?
Related Medications in Nonsteroidal Anti-Inflammatory Drug (NSAID)
Other drugs grouped near meloxicam - same-class peers and common alternatives.
abatacept
Orencia
Orencia is a medicine that helps to reduce inflammation.
Compare with meloxicam →
acetaminophen
Tylenol
Acetaminophen (Tylenol) is a medicine that can relieve pain and reduce fever.
Compare with meloxicam →
acetaminophen/hydrocodone
Vicodin, Norco
This medicine contains acetaminophen and hydrocodone.
Compare with meloxicam →
acetaminophen/oxycodone
Percocet
Percocet is a strong pain medicine.
Compare with meloxicam →
adalimumab
Humira
Idacio is a medicine that blocks a protein called TNF.
Compare with meloxicam →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for meloxicam: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 55,835.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 6.34%.
- indapamide Δ 0.00 pts · 17,199 reports · Thiazide-Like Diuretic 6.34%death share
- nitrofurantoin Δ 0.00 pts · 15,757 reports · Nitrofuran Antibiotic 6.35%death share
- icosapent ethyl Δ 0.03 pts · 7,801 reports · Omega-3 Fatty Acid (EPA) 6.37%death share
- latanoprost Δ 0.04 pts · 48,513 reports · Prostaglandin Analog (Ophthalmic) 6.38%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on meloxicam
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for meloxicam
The FDA label for meloxicam (sold under brand names such as Mobic) classifies it as a prescription-only medication in the Nonsteroidal Anti-Inflammatory Drug (NSAID) class. Meloxicam treats the symptoms of osteoarthritis and rheumatoid arthritis. Official labeling lists 4 commonly reported side effects, including Diarrhea, Upper respiratory infection, Upset stomach.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 55,835 voluntary reports. The database also lists 17 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS shows a generic unit cost of $10.63.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: August 8, 2024
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages